ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 489

S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)

Adéla Navrátilová1, Jiří Baloun 2, Hana Hulejová 2, Karel Pavelka 3, Jiří Vencovský 3, Ladislav Senolt 3 and Lucie Andrés Cerezo 1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Neutrophil Extracellular Traps, rheumatoid arthritis (RA) and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: S100A11 protein, a member of S100 family, has been associated with several autoimmune inflammatory conditions such as rheumatoid arthritis (RA). Moreover, its pro-inflammatory effect on mononuclear cells has been reported (1). Although the pathogenesis of autoimmune diseases is not fully understood, the formation of NETs seem to play a certain role. Recent data indicate that some DAMPs including S100A8/A9 are released via NETosis and can further augment inflammatory responses.

Methods: To assess the expression of S100A11 by neutrophils of RA synovial tissue (n=5), immunofluorescence staining of S100A11 and myeloperoxidase (MPO) was performed. The levels of S100A11 and MPO in RA synovial fluid (n=24) and serum (n=36) were measured by ELISAs (RayBiotech and Abcam). For in vitro experiments, NETosis was induced by adding phorbol 12-myristate 13-acetate (PMA) to the neutrophils purified from peripheral blood of RA patients (n=7). Release of NETs was visualised by immunocytochemistry (n=4-7) and the presence of S100A11 in supernatants was analysed by ELISA (RayBiotech). Neutrophils purified from healthy donors were stimulated by S100A11 and the release of cytokines TNFα, IL-6 was measured by ELISA (RayBiotech).

Results: S100A11 was expressed by synovial tissue neutrophils of the RA patients (n=5). The levels of S100A11 in the serum and in the synovial fluid of patients with RA were significantly associated with the levels of neutrophil MPO (r=0.463, p=0.005 and r=0.500, p=0.013). We demonstrated that the neutrophils treated by LPS (n=7) did not up-regulate the secretion of S100A11 compared to unstimulated controls (0.28±0.07 vs. 0.25±0.06; p=ns). However, the release of S100A11 was significantly up-regulated in PMA stimulated neutrophils undergoing NETosis compared to untreated controls (0.30±0.08 vs. 1.14±0.22; p=0.006). Moreover, our results showed that DPI treatment abolished PMA-induced S100A11 secretion. By immunofluorescence staining we demonstrated that the neutrophils activated by PMA release NETs containing S100A11 protein whereas cells stimulated by DPI+PMA were not able to form NETs. In addition, extracellular S100A11 did not modulate the secretion of pro-inflammatory cytokines TNFα and IL-6 by human neutrophils (n=5).

Conclusion: Here we show for the first time that the release of S100A11 by neutrophils could be dependent on NETosis. Moreover, extracellular S100A11 does not further augment the inflammatory response of neutrophils in RA.

Acknowledgement: Supported by MHCR 023728 and SVV – 260373
References: (1) Andrés Cerezo et al., Arthritis Research & Therapy (2017) 19:79, DOI 10.1186/s13075-017-1288-y


Disclosure: A. Navrátilová, None; J. Baloun, None; H. Hulejová, None; K. Pavelka, AbbVie, 8, Abbvie, 5, 8, Amgen, 5, 8, BMS, 8, Egis, 5, 8, Lilly, 5, 8, MSD, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 8; J. Vencovský, projeMinistry of Health, Czech Republic, project 00023728, 2; L. Senolt, None; L. Andrés Cerezo, None.

To cite this abstract in AMA style:

Navrátilová A, Baloun J, Hulejová H, Pavelka K, Vencovský J, Senolt L, Andrés Cerezo L. S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/s100a11-calgizzarin-is-released-during-neutrophil-extracellular-traps-nets-formation-in-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/s100a11-calgizzarin-is-released-during-neutrophil-extracellular-traps-nets-formation-in-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology